This study evaluated the efficacy and safety of combination therapy using the multitargeted angiogenesis inhibitor (anlotinib) combined with immunotherapeutic PD‐1/PD‐L1 inhibitors as second‐line and subsequent treatment options for advanced SCLC patients. Here, PDCD1 is linked to small cell lung carcinoma.